Publication
Article Metrics
Citations
Online attention
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
DOI:
10.4161/mabs.28612
PMID:
24670876
Authors:
Stevan
Shaw
(UCB Pharma)
,
Tim
Bourne
(UCB Pharma)
,
Chris
Meier
(UCB Pharma)
,
Bruce
Carrington
(UCB Pharma)
,
Rich
Gelinas
(UCB Pharma)
,
Alistair
Henry
(UCB Pharma)
,
Andrew
Popplewell
(UCB Pharma)
,
Ralph
Adams
(UCB Pharma)
,
Terry
Baker
(UCB Pharma)
,
Steve
Rapecki
(UCB Pharma)
,
Diane
Marshall
(UCB Pharma)
,
Adrian
Moore
(UCB Pharma)
,
Helen
Neale
(UCB Pharma)
,
Alastair
Lawson
(UCB Pharma)
Co-authored by industrial partner:
Yes
Type:
Journal Paper
Journal:
Mabs
, VOL 6
, PAGES 773 - 781
State:
Published (Approved)
Published:
April 2014

Abstract: Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at “Site 3”, blocking the interaction with the signaling co-receptor gp130.
Journal Keywords: interleukin 6; IL-6; antibody; site 3; gp130; olokizumab; neutralization; structure
Subject Areas:
Biology and Bio-materials,
Medicine,
Chemistry
Instruments:
I02-Macromolecular Crystallography
Added On:
18/11/2015 14:32
Documents:
Discovery and characterization of olokizumab.pdf
Discipline Tags:
Non-Communicable Diseases
Autoimmune Diseases
Health & Wellbeing
Biochemistry
Chemistry
Structural biology
Drug Discovery
Life Sciences & Biotech
Technical Tags:
Diffraction
Macromolecular Crystallography (MX)